Header

UZH-Logo

Maintenance Infos

Browse by Creators

Navigate back| Up a level
Export as
Number of items: 6.

Creutzig, U; Zimmermann, M; Bourquin, J P; Dworzak, M N; Kremens, B; Lehrnbecher, T; von Neuhoff, C; Sander, A; von Stackelberg, A; Schmid, I; Starý, J; Steinbach, D; Vormoor, J; Reinhardt, D (2012). Favorable outcome in infants with AML after intensive first- and second-line treatment: an AML-BFM study group report. Leukemia, 26(4):654-661.

Creutzig, U; Zimmermann, M; Bourquin, J P; Dworzak, M N; Fleischhack, G; von Neuhoff, C; Sander, A; Schrauder, A; von Stackelberg, A; Ritter, J; Starý, J; Reinhardt, D (2011). CNS irradiation in pediatric acute myleoid leukemia: equal results by 12 or 18 Gy in studies AML-BFM98 and 2004. Pediatric Blood & Cancer, 57(6):986-992.

Creutzig, U; Zimmermann, M; Bourquin, J P; Dworzak, M N; von Neuhoff, C; Sander, A; Schrauder, A; Teigler-Schlegel, A; Stary, J; Corbacioglu, S; Reinhardt, D (2011). Second induction with high-dose cytarabine and mitoxantrone: different impact on pediatric AML patients with t(8;21) and with inv(16). Blood, 118(20):5409-5415.

Sander, A; Linseisen, J; Rohrmann, S (2010). Intake of heterocyclic aromatic amines and the risk of prostate cancer in the EPIC-Heidelberg cohort. Cancer Causes & Control, 22(1):109-114.

von Neuhoff, C; Reinhardt, D; Sander, A; Zimmermann, M; Bradtke, J; Betts, D R; Zemanova, Z; Stary, J; Bourquin, J P; Haas, O A; Dworzak, M N; Creutzig, U (2010). Prognostic impact of specific chromosomal aberrations in a large group of pediatric patients with acute myeloid leukemia treated uniformly according to trial AML-BFM 98. Journal of Clinical Oncology, 28(16):2682-2689.

Marangi, P A; Forsayeth, J R; Mittaud, P; Erb-Vögtli, S; Blake, D J; Moransard, M; Sander, A; Fuhrer, C (2001). Acetylcholine receptors are required for agrin-induced clustering of postsynaptic proteins. The EMBO Journal, 20(24):7060-7073.

This list was generated on Fri Nov 24 04:07:32 2017 CET.